Katalog der Deutschen Nationalbibliothek

Expertensuche ?

Servicezeiten in Frankfurt am Main ab 1. Dezember 2025: Montag bis Freitag 9–18 Uhr und Samstag 10–16 Uhr
Service hours in Frankfurt am Main from 1 December 2025: Monday to Friday 9:00-18:00 and Saturday 10:00-16:00

Dienstag 9. Dezember 2025: Die Lesesäle der Deutschen Nationalbibliothek in Leipzig öffnen wegen einer Personalversammlung erst ab 13 Uhr. // Tuesday 9 December 2025: The reading rooms of the German National Library in Leipzig will open at 13:00 due to a staff assembly.

Ergebnis der Suche nach: "Originator"
im Bestand: Gesamter Bestand

61 - 70 von 77

	61	Evaluation of adverse events focusing on infection associated with infliximab originator and biosimilar using a spontaneous reporting system database Enthalten in Journal of pharmaceutical health care and sciences Bd. 5, 7.10.2019, Nr. 1, date:12.2019: 1-4
	62	Forty-Eight-Month Monitoring of Disease Activity in Patients with Long-Standing Rheumatoid Arthritis Treated with TNF-α Inhibitors: Time for Clinical Outcome Prediction and Biosimilar vs Biologic Originator Performance Enthalten in Clinical drug investigation Bd. 44, 31.1.2024, Nr. 3, date:3.2024: 141-148
	63	Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog®) in Patients with Type 1 Diabetes After 24 Weeks: A Randomized Open-Label Study Enthalten in BioDrugs Bd. 36, 17.9.2022, Nr. 6, date:11.2022: 761-772
	64	Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis Enthalten in BioDrugs Bd. 37, 23.3.2023, Nr. 3, date:5.2023: 409-420
	65	Impact of switching from the originator adalimumab to a biosimilar: a retrospective cohort study Enthalten in BMC immunology Bd. 26, 3.7.2025, Nr. 1, date:12.2025: 1-13
	66	Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept Enthalten in BioDrugs Bd. 35, 26.10.2021, Nr. 6, date:11.2021: 765-772
	67	Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies Enthalten in Advances in therapy Bd. 35, 6.8.2018, Nr. 9, date:9.2018: 1295-1332
	68	Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent Enthalten in BioDrugs Bd. 32, 29.9.2018, Nr. 5, date:10.2018: 397-404
	69	Outcomes Following Adalimumab Bio-originator to Biosimilar Switch—A Comparison Using Real-world Patient- and Physician-Reported Data in European Countries Enthalten in Rheumatology and therapy Bd. 10, 12.1.2023, Nr. 2, date:4.2023: 433-445
	70	Physicochemical and Functional Comparability Between the Proposed Biosimilar Rituximab GP2013 and Originator Rituximab Enthalten in BioDrugs Bd. 27, 7.5.2013, Nr. 5, date:10.2013: 495-507

61 - 70 von 77

Alle Materialarten > Online Ressourcen (77)

Alle Kataloge/Sammlungen

Hochschulschriften (3)

Alle Standorte > Online (frei zugänglich) (77)

Aktionen

Administration